Floatz logo

Alpha-Type-1 Polarized Dendritic Cells

Refractory Melanoma

Roswell Park Cancer InstituteCell therapyPhase 2Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

449 Active assets in the Refractory Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Tebentafusp
Immunocore Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Alpha-Type-1 Polarized Dendritic Cells is also rated in:

breast cancerDormant
C
Indicative ·
37 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →
HLA-A2 Positive Cells PresentDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →